Geographic Atrophy Market Size, Share, Growth, Analysis: By Age Group: 60-75 Years, Above 75 Years; By Treatment: Medications, Supplements, Others; By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy; Regional Analysis; Market Dynamics: SWOT Analysis, PESTEL Analysis; Supplier Landscape; 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Geographic Atrophy Market Overview: 8 Major Market 
    3.1    Geographic Atrophy Market Historical Value (2017-2023) 
    3.2    Geographic Atrophy Market Forecast Value (2024-2032)
4    Vendor Positioning Analysis
    4.1    Key Vendors
    4.2    Prospective Leaders
    4.3    Niche Leaders
    4.4    Disruptors
5    Geographic Atrophy Market: Disease Overview 
    5.1    Guidelines and Stages
    5.2    Pathophysiology
    5.3    Screening and Diagnosis
    5.4    Therapy Pathway 
6    Patient   Profile
    6.1    Patient Profile Overview
    6.2    Patient Psychology and Emotional Impact Factors
    6.3    Risk Assessment and Therapy Success Rate
7    Geographic  Atrophy Market Epidemiology Scenario and Forecast – 8 Major Markets
    7.1    8MM Epidemiology Scenario Overview (2017-2032)
        7.1.1    Prevalence, by Country
            7.1.1.1    U.S.
            7.1.1.2    U.K.
            7.1.1.3    EU4
            7.1.1.4    India 
            7.1.1.5    Japan
        7.1.2    Mortality by Country
            7.1.2.1    U.S.
            7.1.2.2    U.K.
            7.1.2.3    EU4
            7.1.2.4    India 
            7.1.2.5    Japan
        7.1.3    Treatment Seeking Rate by Country
            7.1.3.1    U.S.
            7.1.3.2    U.K.
            7.1.3.3    EU4
            7.1.3.4    India 
            7.1.3.5    Japan
8    Geographic Atrophy Market Landscape: 8 Major Market*
    8.1    Geographic Atrophy Market: Developers Landscape
        8.1.1    Analysis by Year of Establishment
        8.1.2    Analysis by Company Size
        8.1.3    Analysis by Region
    8.2    Geographic Atrophy Market: Product Landscape 
        8.2.1    Analysis by Treatment
9    Geographic Atrophy Market Challenges and Unmet Needs
    9.1    Therapy Pathway Challenges
    9.2    Compliance and Drop-Out Analysis
    9.3    Awareness and Prevention Gaps
10    Cost of Therapy    
11    Geographic Atrophy: Market Dynamics
    11.1    Market Drivers and Constraints
    11.2    SWOT Analysis
        11.2.1    Strengths
        11.2.2    Weaknesses
        11.2.3    Opportunities
        11.2.4    Threats
    11.3    PESTEL Analysis
        11.3.1    Political 
        11.3.2    Economic 
        11.3.3    Social 
        11.3.4    Technological 
        11.3.5    Legal 
        11.3.6    Environment
    11.4    Porter’s Five Forces Model
        11.4.1    Bargaining Power of Suppliers
        11.4.2    Bargaining Power of Buyers
        11.4.3    Threat of New Entrants
        11.4.4    Threat of Substitutes
        11.4.5    Degree of Rivalry
    11.5    Key Demand Indicators 
    11.6    Key Price Indicators
    11.7    Industry Events, Initiatives, and Trends 
    11.8    Value Chain Analysis
12    Geographic Atrophy Market Segmentation: 8 Major Markets
    12.1    Geographic Atrophy Market by Age Group
        12.1.1    Market Overview
        12.1.2    60-75 Years
        12.1.3    Above 75 Years
    12.2    Geographic Atrophy Market by Treatment
        12.2.1    Market Overview
        12.2.2    Medications
        12.2.3    Supplements
        12.2.4    Others
    12.3    Geographic Atrophy Market by Distribution Channel
        12.3.1    Market Overview
        12.3.2    Hospital Pharmacy
        12.3.3    Retail Pharmacy
        12.3.4    Online Pharmacy
    12.4    Geographic Atrophy Market by Region
        12.4.1    Market Overview
        12.4.2    United States
        12.4.3    EU-4 and the United Kingdom
            12.4.3.1    Germany
            12.4.3.2    France
            12.4.3.3    Italy
            12.4.3.4    Spain
            12.4.3.5    United Kingdom
        12.4.4    Japan
        12.4.5    India
13    United  States Geographic Atrophy Market (2017-2032)
    13.1    United States Geographic Atrophy Market Historical Value (2017-2023) 
    13.2    United States Geographic Atrophy Market Forecast Value (2024-2032)
    13.3    United States Geographic Atrophy Market by Age Group
        13.3.1    Market Overview
        13.3.2    60-75 Years
        13.3.3    Above 75 Years
    13.4    United States Geographic Atrophy Market by Treatment
        13.4.1    Market Overview
        13.4.2    Medications
        13.4.3    Supplements
        13.4.4    Others
    13.5    United States Geographic Atrophy Market by Distribution Channel
        13.5.1    Market Overview
        13.5.2    Hospital Pharmacy
        13.5.3    Retail Pharmacy
        13.5.4    Online Pharmacy
14    EU-4 and  United Kingdom Geographic Atrophy Market (2017-2032)
    14.1    EU-4 and United Kingdom Geographic Atrophy Market Historical Value (2017-2023)
    14.2    EU-4 and United Kingdom Geographic Atrophy Market Forecast Value (2024-2032)
    14.3    EU-4 and United Kingdom Geographic Atrophy Market by Age Group
        14.3.1    Market Overview
        14.3.2    60-75 Years
        14.3.3    Above 75 Years
    14.4    EU-4 and United Kingdom Geographic Atrophy Market by Treatment
        14.4.1    Market Overview
        14.4.2    Medications
        14.4.3    Supplements
        14.4.4    Others
    14.5    EU-4 and United Kingdom Geographic Atrophy Market by Distribution Channel
        14.5.1    Market Overview
        14.5.2    Hospital Pharmacy
        14.5.3    Retail Pharmacy
        14.5.4    Online Pharmacy
15    Japan Geographic Atrophy Market
    15.1    Japan Geographic Atrophy Market Historical Value (2017-2023) 
    15.2    Japan Geographic Atrophy Market Forecast Value (2024-2032)
    15.3    Japan Geographic Atrophy Market by Age Group
        15.3.1    Market Overview
        15.3.2    60-75 Years
        15.3.3    Above 75 Years
    15.4    Japan Geographic Atrophy Market by Treatment
        15.4.1    Market Overview
        15.4.2    Medications
        15.4.3    Supplements
        15.4.4    Others
    15.5    Japan Geographic Atrophy Market by Distribution Channel
        15.5.1    Market Overview
        15.5.2    Hospital Pharmacy
        15.5.3    Retail Pharmacy
        15.5.4    Online Pharmacy
16    India Geographic Atrophy Market
    16.1    India Geographic Atrophy Market (2017-2032) Historical Value (2017-2023) 
    16.2    India Geographic Atrophy Market (2017-2032) Forecast Value (2024-2032)
    16.3    India Geographic Atrophy Market by Age Group
        16.3.1    Market Overview
        16.3.2    60-75 Years
        16.3.3    Above 75 Years
    16.4    India Geographic Atrophy Market by Treatment
        16.4.1    Market Overview
        16.4.2    Medications
        16.4.3    Supplements
        16.4.4    Others
    16.5    India Geographic Atrophy Market by Distribution Channel
        16.5.1    Market Overview
        16.5.2    Hospital Pharmacy
        16.5.3    Retail Pharmacy
        16.5.4    Online Pharmacy
17    Regulatory Framework
    17.1    Regulatory Overview
    17.2    US FDA
    17.3    EU EMA
    17.4    INDIA CDSCO
    17.5    JAPAN PMDA
    17.6    Others
18    Patent Analysis
    18.1     Analysis by Type of Patent
    18.2     Analysis by Publication Year
    18.3     Analysis by Issuing Authority
    18.4     Analysis by Patent Age
    18.5     Analysis by CPC Analysis
    18.6     Analysis by Patent Valuation 
    18.7     Analysis by Key Players
19    Clinical Trial Analysis
    19.1    Analysis by Trial Registration Year
    19.2    Analysis by Trial Status
    19.3    Analysis by Trial Phase
    19.4    Analysis by Therapeutic Area
    19.5    Analysis by Geography
20    Grant Analysis
    20.1    Analysis by Year
    20.2    Analysis by Amount Awarded
    20.3    Analysis by Issuing Authority
    20.4    Analysis by Grant Product
    20.5    Analysis by Funding Institute
    20.6    Analysis by Departments
    20.7    Analysis by Recipient Organization
21    Strategic Initiatives
    21.1     Analysis by Partnership Instances
    21.2     Analysis by Type of Partnership
    21.3     Analysis by Leading Players
    21.4     Analysis by Geography
22    Funding  and Investment Analysis
    22.1    Analysis by Funding Instances
    22.2    Analysis by Type of Funding
    22.3    Analysis by Funding Amount
    22.4    Analysis by Leading Players
    22.5    Analysis by Leading Investors
    22.6    Analysis by Geography
23    Supplier  Landscape
    23.1    Market Share by Top 5 Companies
    23.2    Apellis Pharmaceuticals, Inc.
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications 
    23.3    Iveric Bio 
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Alkeus Pharmaceuticals Inc. 
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    Hemera Biosciences 
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Allegro Ophthalmics 
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Stealth BioTherapeutics 
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Novartis AG 
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Regenerative Patch Technologies, LLC 
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    F. Hoffmann-La Roche AG 
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
    23.11    Gensight Biologics 
        23.11.1    Financial Analysis
        23.11.2    Product Portfolio
        23.11.3    Demographic Reach and Achievements
        23.11.4    Mergers and Acquisitions
        23.11.5    Certifications
    23.12    NGM Biopharmaceuticals  
        23.12.1    Financial Analysis
        23.12.2    Product Portfolio
        23.12.3    Demographic Reach and Achievements
        23.12.4    Mergers and Acquisitions
        23.12.5    Certifications 
    23.13    AstraZeneca PLC 
        23.13.1    Financial Analysis
        23.13.2    Product Portfolio
        23.13.3    Demographic Reach and Achievements
        23.13.4    Mergers and Acquisitions
        23.13.5    Certifications
    23.14    Lineage Cell Therapeutics   
        23.14.1    Financial Analysis
        23.14.2    Product Portfolio
        23.14.3    Demographic Reach and Achievements
        23.14.4    Mergers and Acquisitions
        23.14.5    Certifications
24    Geographic Atrophy Market – Distribution Model (Additional Insight)
    24.1     Overview 
    24.2     Potential Distributors 
    24.3     Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Payment Methods (Additional Insight)
    26.1    Government Funded
    26.2    Private Insurance
    26.3    Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.